Literature DB >> 24438719

From translation to version management: a history and review of methods for the cultural adaptation of the EuroQol five-dimensional questionnaire.

Rosalind Rabin1, Claire Gudex1, Caroline Selai2, Michael Herdman3.   

Abstract

The EuroQol five-dimensional (EQ-5D) questionnaire is used worldwide as a patient-reported outcome (PRO) instrument for the measurement and valuation of health. Several variants of the instrument now exist, including versions with three and five levels of severity and one for respondents aged 8 to 14 years. From the outset, a demand for new language versions of the EQ-5D questionnaire meant that there was a need to implement standardized procedures, which ensured that such versions were produced following international recommendations for the cultural adaptation of patient-reported outcomes. The availability of new variants and formats of the instrument, such as telephone-administered or electronic formats, complicated the task of providing and controlling the quality of cultural adaptations. Although cultural adaptations of the instrument are widely used, the procedures currently used to produce them have not been widely disseminated. The present article therefore describes the evolution of the production of other language versions of the instrument from the earliest days of simultaneous production and translation of the EQ-5D questionnaire to the more recent, broader-based strategy of version management. We describe current adaptation procedures and innovations within those procedures. We also describe how version management is organized within the EuroQol Group, review aspects related to quality control, and provide an overview of the number of currently available language versions for each variant of the EQ-5D questionnaire: three-level, five-level, and youth versions. We conclude by discussing some of the relevant issues related to cultural adaptation for frequently used instruments such as the EQ-5D questionnaire.
© 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Published by International Society for Pharmacoeconomics and Outcomes Research (ISPOR) All rights reserved.

Entities:  

Keywords:  EQ-5D; cultural adaptation; patient-reported outcomes; version management

Mesh:

Year:  2014        PMID: 24438719     DOI: 10.1016/j.jval.2013.10.006

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  76 in total

1.  Is Parkinson's Disease Associated with Increased Mortality, Poorer Outcomes Scores, and Revision Risk After THA? Findings from the Swedish Hip Arthroplasty Register.

Authors:  Alex Leigh Wojtowicz; Maziar Mohaddes; Daniel Odin; Erik Bülow; Szilard Nemes; Peter Cnudde
Journal:  Clin Orthop Relat Res       Date:  2019-06       Impact factor: 4.176

2.  Lung function is associated with minimal EQ-5D changes over time in patients with systemic sclerosis.

Authors:  Jacopo Ciaffi; Nina M van Leeuwen; Sophie I E Liem; Maarten K Ninaber; Tom W J Huizinga; Jeska K de Vries-Bouwstra
Journal:  Clin Rheumatol       Date:  2020-01-24       Impact factor: 2.980

3.  Further evidence on EQ-5D-5L preference inversion: a Brazil/U.S. collaboration.

Authors:  Benjamin M Craig; Andréa L Monteiro; Michael Herdman; Marisa Santos
Journal:  Qual Life Res       Date:  2017-05-08       Impact factor: 4.147

4.  eHealth-supported decentralized multi-disciplinary care for gout involving rheumatology, pharmacy, and dietetics: proof-of-concept study.

Authors:  Alyssa Howren; Nicole W Tsao; Hyon K Choi; Kam Shojania; Alison Kydd; Russell Friesen; J Antonio Avina-Zubieta; Mary A De Vera
Journal:  Clin Rheumatol       Date:  2019-11-13       Impact factor: 2.980

5.  Enhanced motivational interviewing for reducing weight and increasing physical activity in adults with high cardiovascular risk: the MOVE IT three-arm RCT.

Authors:  Khalida Ismail; Daniel Stahl; Adam Bayley; Katherine Twist; Kurtis Stewart; Katie Ridge; Emma Britneff; Mark Ashworth; Nicole de Zoysa; Jennifer Rundle; Derek Cook; Peter Whincup; Janet Treasure; Paul McCrone; Anne Greenough; Kirsty Winkley
Journal:  Health Technol Assess       Date:  2019-12       Impact factor: 4.014

6.  [Quality of life and vertigo after bilateral cochlear implantation : Questionnaires as tools for quality assurance].

Authors:  T Rader; M Haerterich; B P Ernst; T Stöver; S Strieth
Journal:  HNO       Date:  2018-03       Impact factor: 1.284

7.  Cost-Effectiveness of Erenumab for the Preventive Treatment of Migraine in Patients with Prior Treatment Failures in Sweden.

Authors:  Ronan Mahon; Andrea Lang; Pamela Vo; Jasper Huels; Philip Cooney; Andriy Danyliv; Umakanth Vudumula; Sreelatha Vadapalle; Farooq Maniyar; Peter J Goadsby
Journal:  Pharmacoeconomics       Date:  2021-01-25       Impact factor: 4.981

8.  Health-related quality of life among children, adolescents, and adults with bladder exstrophy-epispadias complex: a systematic review of the literature and recommendations for future research.

Authors:  Michaela Dellenmark-Blom; Sofia Sjöström; Kate Abrahamsson; Gundela Holmdahl
Journal:  Qual Life Res       Date:  2019-02-06       Impact factor: 4.147

9.  Comparing EQ-5D-3L and EQ-5D-5L performance in common cancers: suggestions for instrument choosing.

Authors:  Juan Zhu; Xin-Xin Yan; Cheng-Cheng Liu; Hong Wang; Le Wang; Su-Mei Cao; Xian-Zhen Liao; Yun-Feng Xi; Yong Ji; Lin Lei; Hai-Fan Xiao; Hai-Jing Guan; Wen-Qiang Wei; Min Dai; Wanqing Chen; Ju-Fang Shi
Journal:  Qual Life Res       Date:  2020-09-15       Impact factor: 4.147

10.  The EQ-5D-3L administered by text message compared to the paper version for hard-to-reach populations in a rural South African trauma setting: a measurement equivalence study.

Authors:  Henry G Burnand; Samuel E McMahon; Adrian Sayers; Tembisa Tshengu; Norrie Gibson; Ashley W Blom; Michael R Whitehouse; Vikki Wylde
Journal:  Arch Orthop Trauma Surg       Date:  2020-08-12       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.